Cardioprotected Percutaneous Coronary Intervention - A Case Study in a Stable Angina Patient

Fast and effective opening of epicardial arteries by thrombolysis or percutaneous coronary intervention (PCI) to restore perfusion to the jeopardised myocardium is considered the cornerstone in the treatment of patients with an acute ST-elevation myocardial infarction (STEMI) leading to a reduction in morbidity and mortality.1 However, despite successful opening of the coronary artery, myocardial reperfusion remains suboptimal (i.e.

Barriers to Implementation of Primary Percutaneous Coronary Intervention in Europe

Coronary heart disease (CHD) remains a leading cause of mortality and disability for both men and women in Europe, accounting for 1.92 million deaths each year.1 One in five women (22%) and one in five men (21%) die from the disease.1 This significant burden necessitates ongoing improvements in patient management and treatment, to minimise the impact of cardiovascular conditions on both patients and healthcare systems.1–3 In 2003, implementation of primary percutaneous coronary intervention (PPCI) accelerated in Europe a

Platelet Function Testing in Clinical Practice - Experience and Views from Europe and the US

Coronary angiography and subsequent percutaneous coronary intervention (PCI) is the appropriate treatment in many patients with moderate- and high-risk acute coronary syndromes (ACS). As ACS and complications after PCI are primarily platelet-driven, adequate antiplatelet therapy is of utmost importance in patients with ACS and after coronary stent implantation. The main antiplatelet agents currently used are salicylates (aspirin) and thienopyridines (clopidogrel, prasugrel). Both aspirin and clopidogrel inhibit platelet function irreversibly.